Not arguing the fact that expenses are more than revenues Malc. That's the definition of "operating at a loss," and goes hand in hand with "not yet cash flow positive." But, realistically, that's the nature of OTC companies...right? They are trying to take the next step up, but haven't quite made it yet.
If they were giving $800K per year to Yaz instead of spending it on R&D and Marketing then I'd have a real problem with it. But they are spending the money in the right ways...getting the product to market. Marketing isn't 100% effective - sometimes it just doesn't work like you want it to. Only time will tell.
Some folks aren't on board, and that's fine. As they say, that's why there's a horse race.
I'm off to work. Best of luck to all.
